News

Prevymis showed less leukopenia and neutropenia compared to valganciclovir during the trial.

Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?

Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.

One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.

Demystifying clinical data for treating invasive AmpC-harboring Enterobacterales.

The federal agency cited concerns regarding the manufacture and delivery of the therapy designed for adults with hepatitis delta virus (HDV).

It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.

Entasis presented follow-up data for its therapy, sulbactam-durlobactam (SUL-DUR), and its phase 3 ATTACK trial. The company is looking at a potential mid-2023 regulatory approval.

With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.

Nearly 150 million people were affected by common symptoms of long COVID in 2020 and 2021, according to an analysis of global data on more than 1.2 million people.

Herpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.

Venatorx Pharmaceuticals is advancing the fight against difficult-to-treat, drug-resistant, gram-negative bacteria with a successful phase 3 clinical trial of its investigational antibiotic cefepime-taniborbactam.

The simple truth is that the long-lasting symptoms of COVID are something we should all be worried about.

The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.

The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.

A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.

Investigators examined the profiles of the HepB-CPG vaccine and HepB-alum vaccines to study the onset of select immune-mediated diseases, herpes zoster, or anaphylaxis.

A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.

Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.

Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.

A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

Our cover story for the October 2022 print edition of Contagion details the original coronavirus.

After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.

Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.

During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.